BE712483A - - Google Patents

Info

Publication number
BE712483A
BE712483A BE712483DA BE712483A BE 712483 A BE712483 A BE 712483A BE 712483D A BE712483D A BE 712483DA BE 712483 A BE712483 A BE 712483A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7104985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE712483(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BE712483A publication Critical patent/BE712483A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BE712483D 1967-03-20 1968-03-20 BE712483A (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEF0051881 1967-03-20

Publications (1)

Publication Number Publication Date
BE712483A true BE712483A (xx) 1968-09-20

Family

ID=7104985

Family Applications (1)

Application Number Title Priority Date Filing Date
BE712483D BE712483A (xx) 1967-03-20 1968-03-20

Country Status (7)

Country Link
US (2) US3485847A (xx)
BE (1) BE712483A (xx)
DE (1) DE1670827C3 (xx)
FR (1) FR7849M (xx)
GB (1) GB1173862A (xx)
IL (1) IL29567A (xx)
NL (1) NL154935B (xx)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883543A (en) * 1969-05-10 1975-05-13 Bayer Ag N-alkyl-1,4-dihydropyridines
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE2005116C3 (de) * 1970-02-05 1980-02-14 Bayer Ag, 5090 Leverkusen Symmetrische 1,4-Dihydropyridin-3,5-dicarbonsäureester
ZA725808B (en) * 1971-08-24 1973-05-30 Bayer Ag A coronary agent in special form and processes for its manufacture
SU432703A3 (xx) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
US3971791A (en) * 1972-03-06 1976-07-27 Bayer Aktiengesellschaft 2-Amino-1,4-dihydropyridine derivatives
US3971790A (en) * 1972-03-06 1976-07-27 Bayer Aktiengesellschaft 2-Amino-1,4-dihydropyridine derivatives
DE2218644C3 (de) * 1972-04-18 1982-08-19 Bayer Ag, 5090 Leverkusen Basische Ester von 1,4-Dihydropyridinen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3922278A (en) * 1972-06-12 1975-11-25 Sterling Drug Inc 4-(3-Nitrophenyl)-3,5-pyridinedicarboxylic acid
US4136187A (en) * 1972-08-12 1979-01-23 Bayer Aktiengesellschaft Antihypertensive 2-amino-4,5-dihydropyridine derivatives
DE2239815C2 (de) * 1972-08-12 1983-02-10 Bayer Ag, 5090 Leverkusen 2-Alkylamino-dihydropyridine, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
US3985376A (en) * 1973-06-04 1976-10-12 Basf Aktiengesellschaft Dye precursors for pressure-sensitive recording material
CH607848A5 (xx) * 1974-06-04 1978-11-30 Bayer Ag
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2650013C3 (de) * 1976-10-30 1981-04-02 Bayer Ag, 5090 Leverkusen 1.4-Dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsäureisopropyl-(2-propoxy-äthyl)-ester, Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
DE2658183A1 (de) * 1976-12-22 1978-07-06 Bayer Ag In 2-position substituierte 1,4- dihydropyridin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
SU706410A1 (ru) * 1978-01-11 1979-12-30 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср 2,6-Диметил-3,5-дикарбметокси-4(0-дифторметоксифенил)-1,4-дигидропиридин,обладающий выраженной гипотензивной активностью и оказывающий действие на функции вегетативной нервной системы
JPS55301A (en) * 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
JPS55124760A (en) * 1979-03-16 1980-09-26 Kanebo Ltd Preparation of 1,4-dihydropyridine derivative or its salt
DE2915355A1 (de) * 1979-04-14 1980-10-23 Nattermann A & Cie Neue 1,4-dihydropyridin-bderivate mit antihypertensiver wirkung
DE3021958A1 (de) * 1980-06-12 1981-12-24 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
YU42386B (en) * 1981-03-13 1988-08-31 Krka Process for preparing 1,4-dihydro-pyridine derivatives
JPS57167911A (en) * 1981-04-09 1982-10-16 Kyoto Yakuhin Kogyo Kk Liquid pharmaceutical of nifedipine
YU41983B (en) * 1981-08-19 1988-04-30 Lek Tovarna Farmacevtskih Process for preparing 1,4-dihydro-pyridine derivatives
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
US4435409A (en) 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
JPS58159490A (ja) * 1982-02-23 1983-09-21 Nikken Kagaku Kk 1,4−ジヒドロピリジン化合物
US4414213A (en) * 1982-03-22 1983-11-08 Mead Johnson & Company Dihydropyridyl cyclic imidate esters and their pharmaceutical use
DE3212736A1 (de) * 1982-04-06 1983-10-13 Bayer Ag, 5090 Leverkusen Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung
JPS58185562A (ja) * 1982-04-22 1983-10-29 Taisho Pharmaceut Co Ltd 1,4−ジヒドロピリジン誘導体
IL68604A0 (en) * 1982-05-21 1983-09-30 Haessle Ab Processes for preparing therapeutically active dihydropyridines and intermediates for the processes
DE3222367A1 (de) * 1982-06-15 1983-12-15 Bayer Ag, 5090 Leverkusen Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung
JPS60197685A (ja) * 1984-03-19 1985-10-07 Shionogi & Co Ltd 4,7―ジヒドロピラゾロ[3,4―b]ピリジン誘導体とその製造法
JPS58146506A (ja) * 1983-01-13 1983-09-01 バイエル・アクチエンゲゼルシヤフト ニフエジピン含有固形製剤
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
JPS59161392A (ja) * 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4529733A (en) * 1983-04-06 1985-07-16 Merrell Dow Pharmaceuticals Inc. Antihypertensive 3-furoyl-1,4-dihydropyridines
US4677101A (en) * 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
EP0141222B1 (en) * 1983-09-26 1989-04-12 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic ester
EP0141221A1 (en) * 1983-09-26 1985-05-15 Nissan Chemical Industries Ltd. 1,4-Dihydropyridine-5-phosphonic acid ester
US4603135A (en) * 1983-10-17 1986-07-29 Takeda Chemical Industries, Ltd. Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates
JPS60109519A (ja) * 1983-11-17 1985-06-15 Nippon Shinyaku Co Ltd ニフェジピン坐剤
US4637930A (en) * 1984-02-08 1987-01-20 Yamanouchi Pharmaceutical Co, Ltd. Transdermal formulation of nicardipine hydrochloride
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
JPS60214778A (ja) * 1984-03-08 1985-10-28 Suntory Ltd Ν置換3,4−ジヒドロピリミジン誘導体ならびにその製造法および用途
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
US4755512A (en) * 1984-04-11 1988-07-05 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
US4895846A (en) * 1984-04-11 1990-01-23 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties
DE3419130A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Nifedipinkombinationspraeparate und verfahren zu ihrer herstellung
DE3419129A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Nifedipinpraeparate und verfahren zu ihrer herstellung
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
US4652573A (en) * 1985-03-14 1987-03-24 Nelson Research & Development Co. Calcium antagonist N-hetero ester 1,4-dihydropyridines
US4833150A (en) * 1985-03-14 1989-05-23 Nelson Research & Development Co. 1,4-dihydropyridines
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
JPS6289662A (ja) * 1985-06-14 1987-04-24 Sankyo Co Ltd 1,4−ジヒドロピリジン誘導体
DE3523544A1 (de) * 1985-07-02 1987-01-15 Bayer Ag Nifedipin kombinationspraeparat
DE3523540A1 (de) * 1985-07-02 1987-01-15 Bayer Ag Dihydropyridin kombinationspraeparat
EP0216542B1 (en) * 1985-09-13 1991-12-11 The Green Cross Corporation Dihydropyridine derivatives
GB8530602D0 (en) * 1985-12-12 1986-01-22 Fujisawa Pharmaceutical Co Heterocyclic compounds
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
US4849436A (en) * 1986-03-11 1989-07-18 Nelson Research & Development Co. 1,4-dihydropyridines
US4814455A (en) * 1986-04-16 1989-03-21 Bristol-Myers Company Dihydro-3,5-dicarboxylates
HU196755B (en) * 1986-09-16 1989-01-30 Gyogyszerkutato Intezet Process for production of new substituated amilid derivatives and medical compositions containing them
US4772596A (en) * 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
JPS63135381A (ja) * 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
GR1002248B (en) * 1988-03-08 1996-04-23 Egyt Gyogyszervegyeszeti Gyar 1,4-dihydropyridine derivatives preparation method
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
ATE128623T1 (de) * 1988-08-02 1995-10-15 Nissan Chemical Ind Ltd Mittel zur verbesserung von arzneimitteleffekten für antitumormittel.
US5286869A (en) * 1988-12-15 1994-02-15 Fujirebio Kabushiki Kaisha 1,4-dihydropyridine derivatives
US5254692A (en) * 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
NL9001752A (nl) * 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
US5438144A (en) * 1991-07-30 1995-08-01 Troponwerke Gmbh & Co. Kg Use of 1,4-dihydropyridines in diabetes
GB9119983D0 (en) * 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
DE4134760A1 (de) * 1991-10-22 1993-07-08 Bayer Ag Aryl-chinolyl-substituierte 1,4-dihydropyridin-dicarbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE4202526A1 (de) * 1992-01-30 1993-08-05 Bayer Ag Neue 4-cinnolinyl- und 4-naphthyridinyl-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE4222770A1 (de) * 1992-07-10 1994-01-13 Bayer Ag Lichtaktivierbare 1-(2-Nitrobenzyl)-substituierte 1,4-Dihydropyridine
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
CA2231195C (en) * 1996-07-08 2003-01-21 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19727350C1 (de) 1997-06-27 1999-01-21 Bayer Ag Verfahren zur Herstellung von Nifedipin
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
IL152021A0 (en) * 2000-04-11 2003-04-10 Sankyo Co Pharmaceutical compositions containing pyridine derivatives
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
RU2007106714A (ru) * 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
HUE025394T2 (en) * 2007-03-21 2016-02-29 Sigma Tau Ind Farmaceuti Preparation for use in type 2 diabetes and complications for use in insulin-resistant pre-diabetic patients
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
CA2642508C (en) 2008-10-31 2011-10-04 Kenneth W. Adams Method of removal of hyperplastic skin lesions
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
AU2013258273A1 (en) 2012-05-07 2014-11-13 Bayer Pharma Aktiengesellschaft Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA3103616A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法

Also Published As

Publication number Publication date
GB1173862A (en) 1969-12-10
DE1670827B2 (de) 1974-03-21
NL154935B (nl) 1977-11-15
NL6803501A (xx) 1968-09-23
IL29567A (en) 1972-02-29
FR7849M (xx) 1970-06-01
US3485847A (en) 1969-12-23
DE1670827C3 (de) 1974-10-24
US3644627A (en) 1972-02-22
DE1670827A1 (de) 1971-03-11

Similar Documents

Publication Publication Date Title
FR7849M (xx)
AT298283B (xx)
AU610966A (xx)
AU1273466A (xx)
BE709308A (xx)
AU23366A (xx)
BE692779A (xx)
BE692778A (xx)
BE692654A (xx)
BE692577A (xx)
BE692553A (xx)
BE703567A (xx)
BE692552A (xx)
BE692493A (xx)
BE702966A (xx)
BE704883A (xx)
BE711389A (xx)
AU1614766A (xx)
BE711058A (xx)
BE692332A (xx)
BE692409A (xx)
BE692375A (xx)
BE710643A (xx)
BE692374A (xx)
BE692199A (xx)

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: BAYER A.G.

Effective date: 19880320